Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Austin Midtown Research & Clinical Trials

Texas Oncology-Austin Midtown participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Midtown (Expand)

Anal Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read More

Phase: III

Biliary Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC

A Phase III Open-Label Multi-Centre Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121) Read More

Phase: III

Bladder Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro

A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

NeoAdj Chemo +/- Nivo/IDO1inh MIBC

A Phase 3 Randomized Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078) Read More

Phase: III

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

Bone Mets

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Brain Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study)

Phase: III

An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Phase: II/III

Breast Cancer

Ph 1/1b TNBC Ovarian

(AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies Read More

Phase: I

Ph2 m7824 triple neg BC

(MS200647_0020) A Phase II Multicenter Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer Read More

Phase: II

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 CDK7 inhibitor HR+ BC

A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (CT7001_001) Read More

Phase: I/II

Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA

A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554) Read More

Phase: III

Ph3 Pembro HR+/HER2- BC

A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More

Phase: III

Ph 3 BYL719 + nabpax TNBC PIK3CA

EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301) Read More

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More

STAR Ph 3 Tuca/Placbo + T-DM1 HER2+

STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016) Read More

Phase: III

Carcinoid

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read More

Phase: III

Cervical Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Colon Cancer

Ph3 Fruq + Placebo CC (FRESCO-2)

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1) Read More

Phase: III

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017) Read More

Phase: II

Endometrial Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Epithelial Carcinomas

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin

Esophageal Cancer

STAR Ph3 Sinti vs Placebo ESCC

A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301 Read More

Phase: III

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Essential Thrombocythemia

STAR PH3 Pacritinib vs MD choice in MF

A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203) Read More

Phase: III

Fallopian Tube Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Gall Bladder Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Gastric Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Head and Neck Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Kaposi's Sarcoma

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Kidney Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Leukemia

STAR Ublituximab+TGR-1202 Cross-over

(UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More

Phase: II

Zanu in Ibrut/Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read More

Phase: II

Ph3b Venetoclax AML

A Phase 3b Single-Arm Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072) Read More

Phase: III

Ph2 Ublituximab+ Umbralisib+ Venetoc CLL

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207) Read More

Phase: II

Liver Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AGEN1884 Adv Refractory cancer

A Phase 1/2 Open-Label Multicenter Study to Evaluate the Safety Pharmacokinetics andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01) Read More

Phase: I/II

Ph 3 Nivo vs. Plac Hepatocell Carc

A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CA209-9DX) Read More

Phase: III

Lung Cancer

Ph 1/1b Immunotherapy Combo in NSCLC

(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More

Phase: I"

Ph 3 Sit+Nivo vs. Docetaxel NSCLC

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Read More

Phase: III

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

Ph 1b FIH XMT-1536 Solid Tumor NaPi2b

A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More

Phase: I

PH3 Neo/Adj Dura Stage 2/3 NSCL (AEGEAN)

A Phase III Double-blind Placebo-controlled Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) (D9106C00001) Read More

Phase: III

PH3 Atezo Carbo Etopo +/- Tira SCL

A Phase III Randomized Double-Blind Placebo-controlled study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in patients with untreated extensive-stage small cell lung cancer (GO41767) Read More

Phase: III

Ph3 Tira atezo NSCL

A PHASE III RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB AN ANTI-TIGIT ANTIBODYIN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717) Read More

Phase: III

STAR-PH3 pral(Blu-667) RET-fusion mNSCLC

A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More

Phase: III

STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More

Phase: III

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

STAR KEAP1/NRF2 NSCLC

CX-839-014 ""KEAPSAKE"": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Read More

Phase: II"

Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Read More

Phase: III

Lymphomas

STAR BV in pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More

Phase: II

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read More

Phase: II

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read More

Phase: I

Zanu in Ibrut/Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read More

Phase: II

TGR-1202 +/- Ublituximab in NHL

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More

Phase: II

EAP BGB-3111 B-Cell Malig

A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216) Read More

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

STAR Ph2 A+AVD +G-CSF or AOAD in CHL

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects Read More

Phase: II

Malignant Adenoma

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Myelofibrosis

STAR PH3 Pacritinib vs MD choice in MF

A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203) Read More

Phase: III

Myelomas

Ph1 SEA-BCMA R/R MM

A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001) Read More

Phase: I

Ph1/2 INCB001158 + SC Dara vs Dara SC MM

A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab Compared toDaratumumab SC in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206) Read More

Phase: I/II

PH3 Dara/Len vs Len NDMM

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021) Read More

Phase: III

PH2 MM Carf Poma & dexa (KPd)

An Open-label Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib Pomalidomide and Dexamethasone (KPd) (20180117) Read More

Phase: II

Ovarian Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph 1b FIH XMT-1536 Solid Tumor NaPi2b

A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More

Phase: I

Pancreatic Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Ph 3 Irino Oxa Flu Leu Pac + GEM mPan

An open-label randomised multicentre phase III study of irinotecan liposome injection oxaliplatin 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (D-US-60010-001) Read More

Phase: III

Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients

Penile Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Peritoneal Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Prostate Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph 2 Nivo+Ipil Ipil mono or Caba CR mPC

A Phase 2 Trial of Nivolumab Plus Ipilimumab Ipilimumab Alone or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (CA209-650) Read More

Phase: II

Ph3 Nivo +/- Doce mPC 7DX

A Phase 3 Randomized Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX) Read More

Phase: III

STAR Ph3 Nirap+Abirat+Pred mCRPC

A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More

Phase: III

Biomarker DNA Defect Men Prostate

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002) Read More

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

STAR Abirat+pred +/- abemaciclib mCRPC

CYCLONE 2: A Phase 2 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Rectal Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017) Read More

Phase: II

Renal Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

PH3 Ate +Cabo Renal Carcinoma

A PHASE III MULTICENTER RANDOMIZED OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994) Read More

Phase: III

Sarcoma

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Skin Cancer

STAR Ph1 CX-4945 Basal Cell Carcinoma

A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More

Phase: I

Solid Tumors

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read More

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

STAR Ph2 Erdafitinib FGFR Solid Tumors

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More

Phase: II

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

Testicular Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Thyroid Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

Urothelial Cancer

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro

A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

STAR Ph 3 Infigratinib UC w/ FGFR3 Alt

QBGJ398-302: Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) Read More

Phase: III

Uterine Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Vaginal Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II

Vulvar Cancer

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read More

Phase: I/II